Heart failure represents a shifting paradigm. The persistent inability of the heart to pump enough blood throughout the body to keep a sufficient supply of oxygen is what is known as patients with cardiovascular disease, also known as cardiac congestive failure or heart failure. Age, diabetic, pressure, and being overweight are some of the most important risk factors for the illness, despite the fact that there are many possible causes. The majority of men who get chronic heart failure. The pathogenesis is complex and multi-faceted and involves structural alterations such the loss of myofibrils, apoptosis, and cytoskeleton disruption, as well as changes in receptor density, cell signaling, collagen formation, Ca2+ homeostasis, and other processes. A more recent working theory holds that heart failure is a disease of left ventricular remodeling that progresses over time and is typically brought on by an index event. This clinical syndrome is marked by reduced cardiac performance and circulatory congestion. Over the past 30 years, there have been significant changes in how heart failure is managed, which have improved patient outcomes and quality of life, at least for those with significantly low left ventricular ejection fractions (HFrEF). This has been made feasible by the discovery of numerous mechanisms underlying the emergence and progression of heart disease, which have been effectively countered by efficient treatments. The list of other potential therapy targets has been compiled and is continually growing in the meantime. In this review, we summarize the proposed future therapies while examining their possible benefits and drawbacks. It also discusses novel pharmacological interventions that could significantly benefit care for people with Heart complications and broaden its application to patients with heart failure as well as other heart failure subtypes.